Biopharmaceuticals

Tabula Rasa HealthCare Partners with RxResults to Provide Pharmacy Risk Management for Health Plans

Retrieved on: 
Thursday, January 28, 2021
Articles, Life sciences, Academic disciplines, Biopharmaceuticals, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Pharmacy, Risk management

MOORESTOWN, N.J., Jan. 28, 2021 /PRNewswire/ --Tabula Rasa HealthCare, Inc."TRHC" (NASDAQ: TRHC), a healthcare technology company advancing safe use of medications, today announced a partnership with RxResults, an evidence-based pharmacy risk management firm, to develop a new competitive model that enables pharmacy plans to identify health plan savings and mitigate medication risk.

Key Points: 
  • MOORESTOWN, N.J., Jan. 28, 2021 /PRNewswire/ --Tabula Rasa HealthCare, Inc."TRHC" (NASDAQ: TRHC), a healthcare technology company advancing safe use of medications, today announced a partnership with RxResults, an evidence-based pharmacy risk management firm, to develop a new competitive model that enables pharmacy plans to identify health plan savings and mitigate medication risk.
  • RxResults offers pharmacy risk management solutions to ensure access to medications proven safe and effective while providing cost control, removing specialty drug conflicts of interest and eliminating misaligned incentives.
  • While Tabula Rasa HealthCare mitigates risk from adverse drug events using its proprietary science, RxResults will enable the partnership to provide clients with proven solutions to mitigate risk and control specialty drug spend and utilization, helping to reduce the overall total cost of healthcare.
  • As the proven industry leader for evidence-based pharmacy risk management, RxResults is uniquely positioned to help plan sponsors mitigate risk, optimize plan performance and generate savings.

Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area

Retrieved on: 
Thursday, January 21, 2021
Life sciences, Pharmaceutical industry, Articles, Biotechnology, Biopharmaceuticals, Biomanufacturing, Food industry, Contract manufacturing organization, WuXi Biologics, GenScript Biotech

From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.

Key Points: 
  • From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.
  • "Northway Biotech reaches an important strategic milestone to further strengthen its leadership by opening a second biomanufacturing facility and its first in the United States.
  • Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide.
  • Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products.

Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area

Retrieved on: 
Thursday, January 21, 2021
Life sciences, Pharmaceutical industry, Articles, Biotechnology, Biopharmaceuticals, Biomanufacturing, Food industry, Contract manufacturing organization, WuXi Biologics, GenScript Biotech

From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.

Key Points: 
  • From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.
  • "Northway Biotech reaches an important strategic milestone to further strengthen its leadership by opening a second biomanufacturing facility and its first in the United States.
  • Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide.
  • Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products.

Cytiva delivers modular biologics factory to Lonza

Retrieved on: 
Thursday, January 14, 2021
Life sciences, Articles, Health sciences, Biopharmaceuticals, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Pharmaceutical industry in China, BeiGene

The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.

Key Points: 
  • The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.
  • Olivier Loeillot, Vice President, Cytiva, says: "In a rapidly-growing industry with increasing needs for mAbsand other key biopharmaceuticals,this facility demonstrates the strength of combining modular manufacturing withsingle-use technologies.
  • Guangzhou Biopark is also home to manufacturing sites for BeiGene and Akesobio, where Cytiva also provided solutions.
  • Cytiva has delivered 77 KUBio and FlexFactory solutions to customers around the world.

Cytiva delivers modular biologics factory to Lonza

Retrieved on: 
Thursday, January 14, 2021
Life sciences, Articles, Health sciences, Biopharmaceuticals, Biomanufacturing, Biotechnology, Food industry, Pharmaceutical industry, Pharmaceutical industry in China, BeiGene

The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.

Key Points: 
  • The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.
  • Olivier Loeillot, Vice President, Cytiva, says: "In a rapidly-growing industry with increasing needs for mAbsand other key biopharmaceuticals,this facility demonstrates the strength of combining modular manufacturing withsingle-use technologies.
  • Guangzhou Biopark is also home to manufacturing sites for BeiGene and Akesobio, where Cytiva also provided solutions.
  • Cytiva has delivered 77 KUBio and FlexFactory solutions to customers around the world.

Signify Health's Biopharmaceutical Clinical and Caregiver Support Services Remove Barriers to Treatment Associated with Complex Drug Therapies

Retrieved on: 
Wednesday, January 13, 2021
Life sciences, Biotechnology, Pharmaceutical industry, Specialty drugs, Biopharmaceuticals, Specialty drugs in the United States, Food and Drug Administration

The services leverage Signify Health's national network of mobile clinicians and community-based social care services to help biopharmaceutical companies and clinical research organizations facilitate treatment for FDA-approved therapies as well as those in Phase III clinical development.

Key Points: 
  • The services leverage Signify Health's national network of mobile clinicians and community-based social care services to help biopharmaceutical companies and clinical research organizations facilitate treatment for FDA-approved therapies as well as those in Phase III clinical development.
  • These services are being made available at a time when the specialty drug market is growing rapidly.
  • The FDA anticipates that by 2025 it will review and approve 10 to 20 complex cell and gene therapies every year.
  • Signify Health delivers its Clinical Support Services for in-line therapies through its national mobile network of nearly 9,000 credentialed providers who are deployable to all 50 states.

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Development of S-Layer Based Vaccines and Cellular Therapeutics

Retrieved on: 
Wednesday, December 30, 2020
Health sciences, Life sciences, Articles, Biopharmaceuticals, Biotechnology, Vaccination, Vaccine, Virology, Drug discovery, Biomanufacturing, Therapy

The collaboration brings together BOKUs S-layer nanotechnology with Avalons expertise in biomanufacturing, cell therapy engineering, and clinical development.

Key Points: 
  • The collaboration brings together BOKUs S-layer nanotechnology with Avalons expertise in biomanufacturing, cell therapy engineering, and clinical development.
  • Professor Sleytr is also a member of Avalons Scientific and Clinical Advisory Board.
  • Adding a coat of an S-layer onto solid surfaces can greatly improve the function of a therapeutic, vaccine, or device.
  • These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

DGAP-News: SHS invests in Swiss-German specialty drug company Develco Pharma

Retrieved on: 
Thursday, December 17, 2020
Life sciences, Health sciences, Health care, Biopharmaceuticals, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Pharmaceutical industry in India, Pharmaceutical industry in China, SHS Gesellschaft für Beteiligungsmanagement mbH, Develco Pharma

Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles

Key Points: 
  • Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles
    Tbingen-based SHS Gesellschaft fr Beteiligungsmanagement mbH is investing from its SHS V fund in the Swiss-German specialty drug company Develco Pharma.
  • Develco has state-of-the-art production operations of its own; its customers include world-leading pharmaceuticals companies that market the products internationally.
  • Develco Pharma has earned an excellent reputation as a developer and producer in this field over the past 14 years.
  • The SHS fund's European based investors include pension funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team.

Global Microbial Contract Biomanufacturing Market (2020 to 2030) - Industry Trends and Global Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 15, 2020
Health, Biotechnology, Life sciences, Articles, Biotechnology, Pharmaceutical industry, Biopharmaceuticals, Biomanufacturing, Food industry

The "Microbial Contract Biomanufacturing Market across Type of Biologic, Type of Microbial Expression System Used, Scale of Operation, End User, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbial Contract Biomanufacturing Market across Type of Biologic, Type of Microbial Expression System Used, Scale of Operation, End User, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market.
  • In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation.
  • What are the key trends within the microbial contract biomanufacturing market?

United States Specialty Pharmaceuticals Market Report 2020: Market will Reach Market Value of US$ 387 Billion by 2026

Retrieved on: 
Tuesday, December 15, 2020
Life sciences, Biotechnology, Health sciences, Biopharmaceuticals, Pharmaceutical industry, Specialty drugs in the United States, Pharmaceutical industry in China

DUBLIN, Dec. 15, 2020 /PRNewswire/ -- The "United States Specialty Pharmaceuticals Market & Forecast by Application (Oncology, Autoimmune, Immunology, HIV, Multiple Sclerosis, Hematology, AMD, HGH, Others), and Companies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 15, 2020 /PRNewswire/ -- The "United States Specialty Pharmaceuticals Market & Forecast by Application (Oncology, Autoimmune, Immunology, HIV, Multiple Sclerosis, Hematology, AMD, HGH, Others), and Companies" report has been added to ResearchAndMarkets.com's offering.
  • It is expected that United States Specialty Pharmaceutical Market will be US$ 387 Billion by 2026.
  • In the United States, the Pharmaceutical market can be categories into two types of drugs Traditional as well as Specialty drugs.
  • During the years, Specialty pharmaceutical has changed much due to speciality drugs being in the final stages of development in the United States.